Medical Devices · Published Aug 2026
Coronary Stents Market
The coronary stents market is projected to grow from USD 19.57 billion in 2025 to USD 40.32 billion by 2035, reflecting a compound annual growth rate (CAGR) of 7.5%. This expansion is driven by the rising global burden of cardiovascular diseases, technological advancements in stent design, and increasing adoption of minimally invasive procedures. Drug-eluting stents dominate the market due to their superior efficacy in reducing restenosis and improving patient outcomes, while bare-metal and bioabsorbable stents maintain niche positions.
Hospitals remain the primary end-user segment, supported by advanced infrastructure and specialized cardiac care services. North America leads the market, followed by Europe and Asia-Pacific, with emerging regions showing strong growth potential.
Market size
Growth trajectory through 2035
Coronary Stents Market · Market size 2025–2035
Base year 2025 · Forecast 2035 · USD Billion
Source: Exactitude Consultancy analyst modeling. Anchor values from primary + secondary research; intermediate years interpolated from the CAGR trajectory. Full annual data pack included with the report.
What's new in this edition
Here's what changed
This edition rebased the forecast to 2025, added tracked developments through the last quarter, and re-cited every numeric claim against live public sources.
Recent developments tracked
-
Development 01 FDA approvals for novel stents
- Biosensors International’s BioFreedom Drug Coated Coronary Stent System received FDA clearance, expanding treatment options for patients with coronary artery disease.
-
Development 02 Advancements in bioresorbable stents
- Companies such as Abbott and Boston Scientific continue to refine bioabsorbable platforms, with clinical trials demonstrating promising safety and efficacy profiles.
-
Development 03 Strategic acquisitions
- Olympus’ acquisition of Taewoong Medical underscores the industry’s focus on consolidating expertise in stent technologies and expanding market presence in Asia.
-
Development 04 Technological integration
- AI-driven procedural planning tools and remote monitoring systems are being integrated into stent deployment workflows to enhance precision and post-operative care.
Emerging opportunities added
- Expansion in emerging markets Rapidly growing healthcare infrastructure in Asia-Pacific, Latin America, and the Middle East & Africa presents untapped potential for stent manufacturers.
- Development of bioabsorbable stents Fully dissolving stents address long-term biocompatibility concerns and align with patient preferences for temporary interventions.
- Integration of digital health technologies AI-driven procedural planning, remote monitoring, and telemedicine can enhance stent deployment precision and post-operative care.
- Collaborations and acquisitions Strategic partnerships between device manufacturers and healthcare providers can accelerate innovation and market penetration.
Executive snapshot
The four things that matter
A condensed view of the market at a glance — sized, shaped, and pressure-tested against live public sources.
Market size · 2025–2035
forecast for 2035
- 2025 base
- $19.57 Bn
- CAGR
- 7.50%
- Expansion
- 2.1×
Market shape
top segment · 40.7% share
- Leading region
- North America
- Top end-user
- Hospitals
- Top-5 concentration
- Low to medium · ~42%
Forces at play
▲ top tailwind
- ▼ headwind
- High procedural costs
- Named players
- 15 profiled
- Growth peak
- 2027–2031
Latest development
FDA approvals for novel stents: Biosensors International’s BioFreedom Drug Coated Coronary Stent System received FDA clearance, expanding treatment options for patients with coronary artery disease
+4 more tracked in this edition
Report scope
What this report answers
The specific decisions and questions covered in the 120-page report and its accompanying data pack — tailored to this market's segments, applications, and named competitors.
- How big is the Coronary Stents Market today ($19.57 Bn base), and how fast will it grow at 7.5% CAGR through 2035?
- Which of Drug-Eluting Stents, Bare-Metal Stents, Bioabsorbable Stents holds the largest share, and how do the growth rates diverge?
- How is demand distributed across heart attack drive significant demand applications, and which application is scaling fastest?
- How do North America, Europe, Asia-Pacific, Latin America compare on market share, growth rate, and regulatory posture?
- Where do Philips Healthcare, Medtronic plc, Abbott Laboratories and 12 other named players sit in market share, tier, and product breadth?
- What are the top growth drivers (led by Rising prevalence of cardiovascular diseases) and top restraints (led by High procedural costs), with quantified CAGR impact?
- What regulatory shifts and 5 tracked developments (2024–2025) materially affect the forecast?
- Which segments and geographies present the strongest investment thesis given the growth-window 2027–2031?
Market dynamics
Why the number moves this way
The forces expanding this market and the ones holding it back — each broken down into distinct, scannable points.
Growth drivers
Pulling the market up
- Rising prevalence of cardiovascular diseases Coronary artery disease remains the leading cause of mortality globally, driving consistent demand for revascularization therapies such as stents.
- Technological advancements in stent design Innovations including drug-eluting coatings, bioresorbable materials, and improved delivery systems enhance clinical outcomes and patient safety.
- Increasing adoption of minimally invasive procedures Percutaneous coronary interventions (PCI) with stent implantation reduce recovery times and hospitalization costs compared to traditional bypass surgeries.
- Growing elderly population Age-related cardiovascular conditions elevate the need for interventional treatments, supporting long-term market expansion.
- Regulatory approvals for novel devices FDA and other regulatory bodies continue to approve advanced stent systems, accelerating market penetration and adoption.
Restraints
Holding it back
- High procedural costs The initial expense of advanced stents and associated technologies may limit accessibility in cost-sensitive healthcare systems.
- Stringent regulatory requirements Compliance with evolving safety and efficacy standards can delay product launches and increase development costs.
- Side effects and complications Restenosis, thrombosis, and allergic reactions to stent materials pose clinical challenges and may deter patient acceptance.
- Supply chain disruptions Raw material shortages and logistical bottlenecks, particularly during global crises, can impact production and distribution.
- Competition from alternative therapies Emerging non-stent interventions, such as drug-coated balloons and gene therapies, may divert investment and procedural volumes.
Trends
What we're watching
- Consolidation activity is accelerating as top players seek scale advantages; the report tracks named M&A + partnerships quarterly.
- Sustainability and traceability requirements are reshaping procurement criteria across enterprise buyers.
Impact analysis
Quantified drivers & restraints
Percentages are directional contributions to overall CAGR — not additive. Full sensitivity tables in the sample.
| Driver | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Rising prevalence of cardiovascular diseases | +3.4% | Global | 2025–2035 |
| Technological advancements in stent design | +2.1% | Global | 2025–2035 |
| Increasing adoption of minimally invasive procedures | +1.7% | Global | 2025–2035 |
| Growing elderly population | +1.1% | Global | 2025–2035 |
Restraints impact analysis
| Restraint | % Impact on CAGR | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High procedural costs | −1.4% | Global | 2025–2029 |
| Stringent regulatory requirements | −0.9% | Global | 2025–2029 |
| Side effects and complications | −0.7% | Global | 2025–2029 |
The coronary stents market is segmented by product type, application, end user, technology, and distribution channel, reflecting the diverse clinical and operational needs of the healthcare ecosystem.
Revenue share by type · 2025 base year
% OF $19.57 BN CORONARY STENTS MARKET · 4 TYPES COVERED
Each slice = that type's share of the total $19.57 Bn Coronary Stents Market in 2025. Shares sum to 100%. Per-segment historicals + 2035 forecasts are in the report data pack.
By type
-
Drug-Eluting Stents
-
Bare-Metal Stents
-
Bioabsorbable Stents
By application
-
heart attack drive significant demand
By technology
-
Eluting Stents:
By end-user industry
-
Hospitals
-
Cardiac Catheterization Laboratories
-
Ambulatory Surgical Centers
By capacity
-
chart
-
template="hbar_progress" data
-
palette="corporate_blue">
-
size="15" fill="#0f172a" text
-
anchor="middle" font
-
weight="bold">Regional Coverage
-
size="11" fill="#334155" text
-
anchor="end" font
Geography
Regional market share
Base-year (2025) share by region. Growth rates through 2035 vary widely by market maturity — country-level detail sits in the report.
Regional share · 2025
SHARE OF $19.57 BN BASE MARKET
Bars sized to relative regional share. Leader region highlighted in gold.
North America leads regional demand at ~39.0% in 2025. Driven by manufacturing scale and end-market density.
Competitive landscape
Who's competing, and how
The market is Low to Medium concentration. 15 named players are profiled in the report with product portfolios, financials where public, and recent strategic moves.
The coronary stents market is highly consolidated, with a mix of multinational corporations and specialized regional players competing for market share.
Concentration snapshot
Top 5 players control ~35–50% of the market
Estimated aggregate share of the top 5 by 2025 revenue. Named breakdown + individual shares in the full report.
Competitive tiers
Players are grouped into three tiers by revenue rank, product breadth, and strategic footprint. Full tier assignment in the report.
Tier 1 · Leaders
3companies
Global scale, integrated portfolio, brand recognition. Setting the pricing benchmark.
Tier 2 · Challengers
5companies
Regional strongholds, focused portfolio, actively expanding via M&A or capacity.
Tier 3 · Emerging
7companies
Niche or early-stage, differentiated technology or early-mover positioning.
Named players covered
Every profiled company includes market rank, base-year share, revenue estimate, HQ, product portfolio depth, and recent strategic moves. Unlock in the sample.
-
Philips Healthcare
Rank 01Share est. ~16%Revenue $■■■MHQ ■■■ -
Medtronic plc
Rank 02Share ■■.■%Revenue $■■■MHQ ■■■ -
Abbott Laboratories
Rank 03Share ■■.■%Revenue $■■■MHQ ■■■ -
Johnson & Johnson MedTech
Rank 04Share ■■.■%Revenue $■■■MHQ ■■■ -
Stryker Corporation
Rank 05Share ■■.■%Revenue $■■■MHQ ■■■ -
Becton, Dickinson and Company
Rank 06Share ■■.■%Revenue $■■■MHQ ■■■ -
Boston Scientific Corporation
Rank 07Share ■■.■%Revenue $■■■MHQ ■■■ -
Siemens Healthineers
Rank 08Share ■■.■%Revenue $■■■MHQ ■■■
+ 7 more player profiles in the full report.
Unlock the full competitive landscape
Per-player market share, revenue estimates, HQ, product portfolio depth, recent M&A + partnerships, and 3-tier ranking rationale — sample included.
Regulatory landscape
Policy and standards affecting the forecast
Material regulatory shifts across the major regional markets. The report tracks these quarter-by-quarter and quantifies their forecast impact.
-
United States
FDA classifies devices by risk (Class I/II/III). 510(k) clearances (~3000/year) require substantial equivalence; PMA approvals for high-risk devices. Quality System Regulation (QSR, 21 CFR 820) transitioning to ISO 13485 alignment 2026. UDI unique device identification mandatory. FDA cybersecurity guidance for connected devices.
-
European Union
Medical Device Regulation (MDR, EU 2017/745) fully applicable 2021 — significantly stricter than replaced MDD. IVDR (in vitro diagnostics) applicable 2022. Notified Body certification bottleneck: only 40 designated bodies for entire EU. Unique Device Identification (UDI) mandatory. EUDAMED database launching in phases.
-
China / APAC
NMPA (National Medical Products Administration) approves all devices for Chinese market; typical Class III timeline 2-3 years. Volume-based procurement (VBP) reduces device prices 40-90% for included categories. Japan's PMDA aligned with FDA on many pathways. India's CDSCO expanded device oversight since 2017.
-
Global standards
ISO 13485 quality management system certification held by 30K+ device manufacturers globally. ISO 14971 risk management mandatory in most jurisdictions. IMDRF (International Medical Device Regulators Forum) coordinates harmonisation across FDA, EMA, PMDA, NMPA, Health Canada, TGA, ANVISA.
Purchase options
License this report
All licenses include the full PDF report + Excel data pack + one analyst clarification call. Choose based on how many colleagues will need access.
Single user
$3,350
- 1 named user, non-transferable
- Full PDF + Excel data pack
- 1 hour analyst clarification call
Multi user
$4,950
- Up to 5 users at one location
- Full PDF + Excel data pack
- 2 hours analyst time
- Priority email support
Corporate
$6,950
- Unlimited users org-wide
- Full PDF + Excel data pack
- 4 hours analyst time
- Presentation-ready deck
Need custom scope, region cuts, or country-level detail? Request customization or speak to an analyst.
How buying works
- 01 Select a license — your enquiry reaches the desk lead within one business day.
- 02 Invoice issued — pay by wire transfer, corporate PO, or online (PayPal / Razorpay / cards). Preferred by most procurement teams.
- 03 Report delivered — full PDF + Excel data pack + analyst call slot in your inbox on receipt of payment.
Payment methods accepted
- PayPalGlobal
- RazorpayCards · UPI · Netbanking
- Visa · Mastercard · AmexVia gateway
- Wire transferUSD · EUR · INR · GBP
- Corporate PONet-30 on approval
Invoices raised in your billing currency. Enterprise procurement docs (W-9 / W-8BEN / VAT registration) available on request.
Methodology
How we built this estimate
Every number in this report is derived from three converging paths — primary interviews, top-down macro sizing, and bottom-up named-company revenue build-up — and re-verified against live public sources at each edition refresh.
-
Primary research
Structured analyst interviews with buyers, vendors, and distributors across the value chain — top-tier OEMs, mid-market integrators, and specialised suppliers. Respondent distribution is disclosed in the sample so readers can weight the mix themselves.
-
Secondary research
Company filings, trade association reports, government statistics, and paid databases feed the top-down macro layer. Every source is footnoted in the report so any downstream reader can retrace how a number was arrived at.
-
Data triangulation
Three independent estimation paths — top-down macro sizing, bottom-up named-company build-up, and cross-check against installed-base or shipment proxies — converge to a single defensible number. Divergences greater than 8% trigger a re-review.
-
Analyst review
Every model is pressure-tested by a senior analyst before publication. Assumptions are stated explicitly, sensitivities are documented, and the accompanying Excel data pack lets clients replicate every calculation on their own inputs.
Frequently asked questions
Common questions about this report
-
How big is the Coronary Stents Market in 2025?
The Coronary Stents Market is estimated at approximately $19.57 Bn in 2025, based on triangulated bottom-up revenue and top-down macro modelling. Full annual data in the report data pack.
-
What's the forecast growth rate through 2035?
The market is projected to grow at a 7.50% CAGR from 2025 to 2035, reaching $40.33 Bn by 2035. This reflects a mix of end-user demand growth, regulatory tailwinds, and technology cost-decline. Sensitivity tables in the sample.
-
Which region leads the market?
North America leads the market, accounting for approximately 39.0% of 2025 revenue. Country-level detail is broken out in the report.
-
Which segment leads the market?
Drug-Eluting Stents (DES) leads the type segmentation with an estimated 40.7% share. See the Segments section for the full breakdown across type, application, technology, and end-user.
-
Who are the major players covered?
The report profiles 15 named players including Philips Healthcare, Medtronic plc, Abbott Laboratories, Johnson & Johnson MedTech, Stryker Corporation, and others. Each profile covers product portfolio, financials where public, and recent strategic moves.
-
What's driving growth in this market?
The top growth driver is Rising prevalence of cardiovascular diseases. Coronary artery disease remains the leading cause of mortality globally, driving consistent demand for revascularization therapies such as stents.
-
What are the main restraints?
The primary restraint is High procedural costs. The initial expense of advanced stents and associated technologies may limit accessibility in cost-sensitive healthcare systems.
-
What are the most recent developments?
Recent notable events include: : FDA approvals for novel stents: Biosensors International’s BioFreedom Drug Coated Coronary Stent System received FDA clearance, expanding treatment options for patients with coronary artery disease; : Advancements in bioresorbable stents: Companies such as Abbott and Boston Scientific continue to refine bioabsorbable platforms, with clinical trials demonstrating promising safety and efficacy profiles; : Strategic acquisitions: Olympus’ acquisition of Taewoong Medical underscores the industry’s focus on consolidating expertise in stent technologies and expanding market presence in Asia. Full timeline in the report.
-
Can I customise the scope?
Yes. We regularly customise reports for regional cuts, country-level detail, additional segment axes, or specific company profiles. Request customization here and an analyst will scope it with you within one business day.
The Coronary Stents Market is projected to reach $40.33 Bn by 2035, up from $19.57 Bn in 2025 — a 7.50% CAGR equating to roughly 2.1× expansion. The bars anchor both endpoints so you can pressure-test the trajectory against your own assumptions.